[go: up one dir, main page]

MX2016004570A - Uso de inhibidores del bromodominio de cbp/ep300 para la inmunoterapia del cáncer. - Google Patents

Uso de inhibidores del bromodominio de cbp/ep300 para la inmunoterapia del cáncer.

Info

Publication number
MX2016004570A
MX2016004570A MX2016004570A MX2016004570A MX2016004570A MX 2016004570 A MX2016004570 A MX 2016004570A MX 2016004570 A MX2016004570 A MX 2016004570A MX 2016004570 A MX2016004570 A MX 2016004570A MX 2016004570 A MX2016004570 A MX 2016004570A
Authority
MX
Mexico
Prior art keywords
cbp
cancer immunotherapy
bromodomain inhibitors
bromodomain
inhibitors
Prior art date
Application number
MX2016004570A
Other languages
English (en)
Inventor
Steven Bellon
James Edmund Audia
Vickie Tsui
Andrea Cochran
Fauber Benjamin
crawford Terry
Magnuson Steven
Cote Alexandre
K Albrecht Brian
GHOSH Srimoyee
Christophe Harmange Jean-
Hatzivassiliou Georgia
JAYARAM Hariharan
Kim Jeong
M Lora Jose
Mellman Ira
Anthony Romero F
M Taylor Alexander
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2016004570A publication Critical patent/MX2016004570A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)

Abstract

La presente invención se relaciona con el uso de inhibidores de bromodominio CBP/EP300 para el tratamiento del cáncer.
MX2016004570A 2013-10-11 2014-10-10 Uso de inhibidores del bromodominio de cbp/ep300 para la inmunoterapia del cáncer. MX2016004570A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361890041P 2013-10-11 2013-10-11
PCT/US2014/060147 WO2015054642A2 (en) 2013-10-11 2014-10-10 Use of cbp/ep300 bromodomain inhibitors for cancer immunotherapy

Publications (1)

Publication Number Publication Date
MX2016004570A true MX2016004570A (es) 2016-09-08

Family

ID=52813753

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016004570A MX2016004570A (es) 2013-10-11 2014-10-10 Uso de inhibidores del bromodominio de cbp/ep300 para la inmunoterapia del cáncer.

Country Status (13)

Country Link
US (1) US20160317632A1 (es)
EP (1) EP3054966A4 (es)
JP (1) JP2016534044A (es)
KR (1) KR20160060765A (es)
CN (1) CN105979958A (es)
AU (1) AU2014331697A1 (es)
BR (1) BR112016007891A2 (es)
CA (1) CA2926946A1 (es)
IL (1) IL245016A0 (es)
MX (1) MX2016004570A (es)
RU (1) RU2016118008A (es)
SG (1) SG11201602815YA (es)
WO (1) WO2015054642A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX373121B (es) 2010-05-14 2020-04-30 Dana Farber Cancer Inst Inc Composiciones y metodos para el tratamiento de leucemia.
CN103037865B (zh) 2010-05-14 2014-10-29 达那-法伯癌症研究所 用于治疗瘤形成、炎性疾病和其他失调的化合物
CA2929652A1 (en) 2013-11-08 2015-05-14 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
MX377534B (es) 2014-02-28 2025-03-10 Tensha Therapeutics Inc Compuestos para usarse en el tratamiento de hiperinsulinemia.
US10124009B2 (en) 2014-10-27 2018-11-13 Tensha Therapeutics, Inc. Bromodomain inhibitors
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
ES2985394T3 (es) 2015-05-29 2024-11-05 Merck Sharp & Dohme Llc Combinación de un antagonista de PD-1 y un oligonucleótido de tipo CpG-C para el tratamiento del cáncer
PE20181068A1 (es) * 2015-10-02 2018-07-04 Dana Farber Cancer Inst Inc Terapia de combinacion de inhibidores de bromodominios y bloqueo de puntos de control
JP6859954B2 (ja) * 2015-11-04 2021-04-14 アステラス製薬株式会社 ジアミノヘテロ環カルボキサミド化合物を有効成分とするがん免疫治療用、及び／又は、免疫活性化用医薬組成物
AU2017302554A1 (en) 2016-07-25 2019-01-31 Epizyme, Inc. CREBBP related cancer therapy
EP3752250B1 (en) 2018-02-16 2022-08-03 Constellation Pharmaceuticals, Inc. P300/cbp hat inhibitors
DK3752497T3 (da) 2018-02-16 2024-09-30 Constellation Pharmaceuticals Inc P300/cbp-hat-hæmmere
TW202028222A (zh) * 2018-11-14 2020-08-01 美商Ionis製藥公司 Foxp3表現之調節劑
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
EP3986470A4 (en) * 2019-06-18 2023-10-04 Dana-Farber Cancer Institute, Inc. SMALL MOLECULE TARGET BROMO/ACETYL PROTEINS AND THEIR USES
CN110170052B (zh) * 2019-06-21 2020-07-10 复旦大学 Cbp-p300抑制剂在肠道损伤疾病中的应用
CN114761013A (zh) 2019-09-27 2022-07-15 迪斯克医药公司 治疗骨髓纤维化和相关病症的方法
CA3153456A1 (en) 2019-10-02 2021-04-08 Stefanie Fluckiger-Mangual Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer
CN110938630B (zh) * 2019-12-20 2023-07-28 中国人民解放军第四军医大学 人b3gnt5基因的用途及相关产品
JP2023528223A (ja) 2020-05-13 2023-07-04 ディスク・メディシン・インコーポレイテッド 骨髄線維症を処置するための抗ヘモジュベリン（ｈｊｖ）抗体
EP4171557A1 (en) 2020-06-25 2023-05-03 Tolremo Therapeutics AG Combination of a cbp/p300 bromodomain inhibitor and a kras inhibitor for the treatment of cancer
CA3183982A1 (en) * 2020-06-25 2021-12-30 Stefanie Fluckiger-Mangual A combination of a cbp/p300 bromodomain inhibitor and an egfr inhibitor for use in treating egfr-mutant nsclc
WO2022184664A1 (en) 2021-03-02 2022-09-09 Boehringer Ingelheim International Gmbh Anticancer combination therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120028912A1 (en) * 2000-02-22 2012-02-02 J.David Gladstone Institute Methods of modulating bromodomains
WO2008157680A2 (en) * 2007-06-21 2008-12-24 The Wistar Institute Methods and compositions for modulating p300/cbp activity
EP2239264A4 (en) * 2007-12-28 2012-01-11 Mitsubishi Tanabe Pharma Corp ANTITUMORAL MEDIUM
GB201020015D0 (en) * 2010-11-25 2011-01-12 Glaxo Group Ltd Method of treatment
AU2012220620A1 (en) * 2011-02-23 2013-10-03 Icahn School Of Medicine At Mount Sinai Inhibitors of bromodomains as modulators of gene expression
WO2013033420A1 (en) * 2011-08-30 2013-03-07 Whitehead Institute For Biomedical Research Methods of downregulating translocated oncogene expression using bromodomain inhibitors
EP2861255B1 (en) * 2012-06-19 2019-10-09 The Broad Institute, Inc. Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy
EP3193866A1 (en) * 2014-09-19 2017-07-26 Genentech, Inc. Use of cbp/ep300 and bet inhibitors for treatment of cancer

Also Published As

Publication number Publication date
AU2014331697A1 (en) 2016-05-05
AU2014331697A9 (en) 2016-05-26
SG11201602815YA (en) 2016-05-30
JP2016534044A (ja) 2016-11-04
IL245016A0 (en) 2016-05-31
RU2016118008A (ru) 2017-11-16
BR112016007891A2 (pt) 2017-12-05
CA2926946A1 (en) 2015-04-16
WO2015054642A9 (en) 2016-04-28
EP3054966A2 (en) 2016-08-17
WO2015054642A2 (en) 2015-04-16
CN105979958A (zh) 2016-09-28
US20160317632A1 (en) 2016-11-03
RU2016118008A3 (es) 2018-07-25
KR20160060765A (ko) 2016-05-30
WO2015054642A3 (en) 2015-06-04
EP3054966A4 (en) 2017-04-19

Similar Documents

Publication Publication Date Title
MX2016004570A (es) Uso de inhibidores del bromodominio de cbp/ep300 para la inmunoterapia del cáncer.
MX2021014956A (es) Formulaciones subcutaneas de anticuerpos anti-cd38 y sus usos.
PH12016501601A1 (en) Cyclopropylamines as lsd1 inhibitors
ZA201605715B (en) Cyclopropylamines as lsd1 inhibitors
GEP20217331B (en) Anti-tigit antibodies
TW201613648A (en) Compounds and compositions for immunotherapy
TW201613860A (en) Cyclopropylamines as LSD1 inhibitors
PH12017501042A1 (en) Anti-cd38 antibodies for treatment of acute myeloid leukemia
NZ731467A (en) Anti-tim3 antibodies and methods of use
ZA201703585B (en) Combination immunotherapy approach for treatment of cancer
PH12016500330B1 (en) Certain chemical entities, compositions, and methods
MX2015012326A (es) Anticuerpos anti-crth2 y su uso.
EP4272738A3 (en) Anti-cd38 antibodies for treatment of acute lymphoblastic leukemia
PH12014501605A1 (en) Anti-lrp5 antibodies and methods of use
IN2013MU00848A (es)
EP3177308A4 (en) Use of peptides that block metadherin-snd1 interaction as treatment for cancer
AU2015311730A8 (en) CaMKII inhibitors and uses thereof
MX2016004573A (es) Inhibidores de nsp4 y metodos de uso.
NZ721832A (en) Solid forms of tenofovir
IN2013MU03768A (es)
MX2015010789A (es) Anticuerpos anti-pcsm.
MY182434A (en) Certain chemical entities, compositions, and methods